Jan C Preiss
Overview
Explore the profile of Jan C Preiss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
362
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schindlbeck K, Becker J, Berger F, Mehl A, Rewitzer C, Geffe S, et al.
Int J Colorectal Dis
. 2016 Oct;
32(1):125-130.
PMID: 27757540
Purpose: Inflammatory bowel disease has been associated with neurological symptoms including restless legs syndrome. Here, we investigated the impact of restless legs syndrome in patients with inflammatory bowel disease on...
12.
Khanna R, Preiss J, MacDonald J, Timmer A
Cochrane Database Syst Rev
. 2015 May;
(5):CD007572.
PMID: 25942580
Background: Ustekinumab (CNTO 1275) and briakinumab (ABT-874) are monoclonal antibodies that target the standard p40 subunit of the cytokines interleukin-12 and interleukin-23 (IL-12/23p40), which are involved in the pathogenesis of...
13.
Karmiris K, Bossuyt P, Sorrentino D, Moreels T, Scarcelli A, Legido J, et al.
J Crohns Colitis
. 2015 Mar;
9(5):382-9.
PMID: 25740813
Background And Aims: Cerebrovascular accidents [CVA] have rarely been reported in inflammatory bowel disease [IBD] patients treated with anti-tumour necrosis alpha [anti-TNF alpha] agents. Our aim here was to describe...
14.
Stallmach A, Nickel L, Lehmann T, Bokemeyer B, Burger M, Huppe D, et al.
World J Gastroenterol
. 2014 Sep;
20(35):12574-80.
PMID: 25253960
Aim: To detect high risk patients with a progressive disease course of ulcerative colitis (UC) requiring immunosuppressive therapy (IT). Methods: A retrospective, multicenter analysis of 262 UC patients from eight...
15.
Armuzzi A, Van Assche G, Reinisch W, Pineton de Chambrun G, Griffiths A, Sladek M, et al.
J Crohns Colitis
. 2012 Mar;
6(4):492-502.
PMID: 22406343
Evidence supporting the importance of assessment of mucosal healing in inflammatory bowel disease has increased in the last years. Mucosal healing has been integrated in the assessment of treatment efficacy...
16.
Wenger S, Nikolaus S, Howaldt S, Bokemeyer B, Sturm A, Preiss J, et al.
J Crohns Colitis
. 2012 Jan;
6(1):21-8.
PMID: 22261524
Background And Aims: The clinical course of Crohn's disease (CD) is highly variable with a subgroup of patients developing a progressive disease course necessitating immunosuppressive therapy (IT). However, reliable, stable...
17.
Timmer A, Preiss J, Motschall E, Rucker G, Jantschek G, Moser G
Cochrane Database Syst Rev
. 2011 Feb;
(2):CD006913.
PMID: 21328288
Background: The effect of psychological interventions in inflammatory bowel diseases (IBD) is controversial. Objectives: To assess the effects of psychological interventions (psychotherapy, patient education, relaxation techniques) on health related quality...
18.
Kapp K, Maul J, Hostmann A, Mundt P, Preiss J, Wenzel A, et al.
Eur J Immunol
. 2010 Oct;
40(11):3128-37.
PMID: 20957752
Oral antigen uptake can induce systemic immune responses ranging from tolerance to immunity. However, the underlying mechanisms are poorly understood, especially in humans. Here, keyhole limpet hemocyanin (KLH), a neoantigen...
19.
Preiss J, Bokemeyer B, Siegmund B, Stange E, Zeitz M, Hoffmann J
Med Klin (Munich)
. 2009 Apr;
104(3):237-43.
PMID: 19337714
The German clinical practice guideline on diagnosis and therapy of Crohn's disease is the result of an evidence-based consensus conference under the auspices of the German Gastroenterologic Society and the...
20.
Usui T, Preiss J, Kanno Y, Yao Z, Bream J, OShea J, et al.
J Exp Med
. 2006 Mar;
203(3):755-66.
PMID: 16520391
T helper type 1 (Th1) development is facilitated by interrelated changes in key intracellular factors, particularly signal transducer and activator of transcription (STAT)4, T-bet, and GATA-3. Here we show that...